Internal Report 20: “mRNA COVID “Vaccines” Have Created a New Class of Multi-Organ/System Disease: “CoVax Disease.” Children from Conception on Suffer Its Devastating Effects.— Histopathology Series—Part 4d”

Summary Pfizer Report 70 (https://dailyclout.io/report-70-part-4c-clinical-evidence-supporting-the-hypothesis-that -autoimmunity-is-one-of-the-principal-pathological-mechanisms-of-harm-from-covid-19-gene-therapy -drugs/) introduced CoVax Disease, a new class of illness that has arisen from the use of mRNA COVID vaccines. CoVax Disease encompasses multiple pathological mechanisms, presents with multi-organ/system involvement, and affects all age groups. This article will focus on the very negative medical impacts on children’s health after receiving mRNA vaccines. Additionally, sex-related effects will be presented. COVID-19 was a disease primarily of older people and those with co-morbidities. Unfortunately, the experimental gene therapy products have devastating effects in young, healthy people of both sexes and all ages from conception upward through the age brackets. Young men have more myo/pericardial disease and more fatalities. Females have more disability and more adverse events overall. As the Cho et al. and Barmada et al. studies document, long-term cardiac disease is one outcome from these drugs. Disease categories associated with gene therapy products are diverse, are unusual in many cases, and can be unusually severe as in MIS-C, sudden death/cardiac arrest, stroke, and turbo cancer, as illustrated by the intracardiac epithelioid sarcoma case reviewed earlier in this report. Children are not exempt from these illnesses. Causation is a complicated topic. However, there is ample support presented herein for concluding that some or many of the medical conditions that arise following an injection of C19 gene therapy products were caused by them.

I. Introduction Since the early medical papers emerging from China in January 2020, it was apparent that the SARS-CoV-2 (SC2) virus preferentially produced disease, COVID-19 (C19), in the elderly with comorbidities. (doi:10.1001/ jama.2020.1585) Some younger people with comorbidities also were at risk, but the risk for severe disease and death in the general population was low. (https://doi.org/10.1016/S0140–6736(20)30211–7) Lipid-nanoparticle coated mRNA drugs (LNP/mRNA) were developed to prevent C19 disease. These drugs along with the adenovirus-vectored products will be referred to collectively as gene therapy products (GTPs). Pfizer Confidential 5.3.6 (https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf) documented COVID-19 as an Adverse Event following inoculation with Pfizer’s

[IMAGE 1 — ORIGINAL SOURCE PAGE 230; PLACE AFTER THE TEXT ABOVE]

BNT162b2 gene therapy product as well as over 140,000 additional adverse events reported in the first ten to twelve weeks. (https://dailyclout.io/pfizer-evidence-so-far-coverups-heart-damage-and-more/) The object of this paper is to review Adverse Event reports following LNP/mRNA gene therapy treatments pertinent to differential age and sex reporting with specific coverage of the zero-to 18-year-old demographic. Specific clinical features of medical conditions afflicting America’s youth following injection of Spikemediated genetic treatment will be discussed. The article will conclude by reviewing the time course of Vaccine Adverse Event Reporting System (VAERS) event reporting relative to United States (U.S.) dosing data. VAERS reports are for the U.S. and its Territories unless otherwise specified. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) maintain VAERS, which is a public resource. (https://wonder.cdc.gov/controller/datarequest/D8) Open VAERS harvests data from VAERS in specific categories and is useful for summary data. (https://openvaers .com/covid-data) In addition to VAERS and Open VAERS, this article will make use of case and small series reports from the medical literature, the FDA-released Pfizer Confidential Documents archive (https://phmpt.org /pfizer-16-plus-documents/), and reporting from individuals including William Makis, MD, Professor Mark Crispin Miller, Ed Dowd and his partners, Jessica Rose, and others. As a caution, the limitations of VAERS are spelled out on the CDC website:

Reports are not detailed enough for many determinations (1), but the utility of the system is as an early warning system (2). Much of the VAERS system activity is invisible to the user, such as what activity occurs from the time a report is filed with the CDC to when it gets posted and after its initial posting. The numbers that are given in response to queries change over time as the system is updated at least every week. Follow-up data are obtained but not posted. Events vary in detail from diagnosis only to detailed reporting of medical data. Some categories return cryptic data like “No Adverse Event,” of which there were 32,072 reports for C19 products from 2020 through mid-June 2023 for all ages with 1,003 associated events including 13 deaths.

[IMAGE 2 — ORIGINAL SOURCE PAGE 231; PLACE AFTER THE TEXT ABOVE]

Here is the information of one fatal case so designated. VAERS ID 1205421 was a 61-year-old male who died less than two days after receiving his second dose of mRNA1273 (Moderna). Someone made the effort to file the report but with no details about this man’s death.

VAERS numbers are generally considered to represent only a fraction of the actual prevalence of the medical conditions reported and for this reason attempts have been made to estimate the true number by estimating what is called the Under Reporting Factor (URF). True prevalence data are hard to find. Steve Kirsch, Jessica Rose, and Mathew Crawford performed detailed calculations of URF concluding that an URF of 41 was justified. (https://www.skirsch.com/covid/Deaths.pdf, https://jessicar.substack.com/p /the-under-reporting-factor-in-vaers)

II. C19 Gene Therapy: Age and Sex Effects A. BNT162b2 and mRNA1273 (LNP/mRNA) Approval Schedule For reference, the following dates are noted:

(https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01)

[IMAGE 3 — ORIGINAL SOURCE PAGE 232; PLACE AFTER THE TEXT ABOVE]

The staggered inoculation of age groups should be kept in mind when looking at data sets that combine age groups. This stagger adds an element of complexity when time series analyses are conducted across age groups. Example: The age brackets in VAERS do not match the age brackets used for the “vaccine” dosing schedule. However, the six-month-old to 5-year-old group has bracketing close to the corresponding dosing brackets. Five-year-olds became eligible to receive BNT162b2 on October 29, 2021, and both mRNA drugs were released for six-month-olds to four-year-olds for BNT162b2 and five-year-olds for mRNA1273 on June 18,

1. The histogram below is a plot of adverse events according to the inoculation schedule showing a spike in event reports following the two authorization dates.

VAERS 6/11/2023

Almost immediately, adverse event reporting in VAERS jumped from nine events to 583 events following the October 21, 2021, authorization and from 121 events (full month before) to 817 events (full month afterward). June was a transition month.

B. VAERS Reports: Age and Sex Differences

[IMAGE 4 — ORIGINAL SOURCE PAGE 233; PLACE AFTER THE TEXT ABOVE]

VAERS adverse event reporting was both age and sex dependent with frequency increasing with age (previous image). Dosing by age bracket or preferably by year age would be helpful if it were available.

Looking at C19 statistics from the CDC, an interesting pattern emerges with C19 cases concentrated in ages 18 to 64 (46 years), while C19 deaths were more prevalent in the age 50 to 85+ bracket (~35 years), above. Like the early reports, these data identify the primary risk factor for mortality with C19 is age along with co-morbidity. The morbidity and mortality from C19 gene therapy products (GTPs) has more representation in the lower age brackets than C19.

C. VAERS Events: 29 Years of Age and Younger, Menarche

VAERS through 5/12/2023

[IMAGE 5 — ORIGINAL SOURCE PAGE 234; PLACE AFTER THE TEXT ABOVE]

Males and females have almost equal adverse event reporting from one to five years, at which age females take over and the lead never changes thereafter (previous image). There is a big increase in female predominance going from the six-to 17-year bracket to the 18-to 29-year bracket as the number of reports in females more than doubles. The age bracket from six to 17 years is too broad given the hormonal and physical changes occurring during this period. Age is reported in VAERS by age bracket although specific age by year data is recorded but is not directly retrievable using defined search terms. A possible explanation for the female shift to a dominant position during adolescence and early adulthood may be related to female sexual development, specifically the onset of menarche. A CDC National Health Statistics Report from 2020 shows the age of onset of menarche follows the approximate time course of the emerging dominance of females in having reported adverse events from LNP/mRNA products. (https://www .cdc.gov/nchs/data/nhsr/nhsr146–508.pdf)

The median age at menarche decreased from 1995 (12.1) to 2013–2017 (11.9). The cumulative probability of menarche at young ages was higher in 2013–2017 compared with 1995.

[IMAGE 6 — ORIGINAL SOURCE PAGE 235; PLACE AFTER THE TEXT ABOVE]

Ed Clark from the WarRoom/DailyClout Pfizer Document Analysis Project was able to retrieve age-byyear data from VAERS for December 2020 through June 2023 with no filtering by vaccine type or manufacturer. Hormonal changes for females, below left, are ramping up during the pre-teen years as females begin to dominate adverse event reporting as shown below on the right.

The polynomial function was used strictly to obtain the general trending of the data over the observed data range and should not be construed to predict outcomes beyond that range. More granular data, age data by year rather than coarse age brackets, for the full data set in VAERS compared with quantitative hormonal changes might help further support or reject this hypothesis.

D. VAERS Events: Ages 40 and Above, Menopause

VAERS 5/12/2023

Women peak at 72% of adverse event reporting from ages 40 to 49 years, as menopause begins for many, and progressively drops down to 63% in the post-menopause age brackets.

[IMAGE 7 — ORIGINAL SOURCE PAGE 236; PLACE AFTER THE TEXT ABOVE]

Spontaneous or natural menopause is recognized retrospectively after 12 months of amenorrhea (previous image). It occurs at an average age of 52 years, but the age of natural menopause can vary widely from 40 to 58 years. (https://www.menopause.org/docs/default-source/2014/nams-recomm-for-clinical-care.pdf)

VAERS May 12, 2023

Overall, the women substantially dominate adverse event reporting in VAERS by more than a two-to-one margin.

E. VAERS Events: Disability after C19 Gene Therapy Similar to adverse event reporting, women also have approximately a two-to-one lead in disability after adverse events after receiving C19 gene therapy products.

[IMAGE 8 — ORIGINAL SOURCE PAGE 237; PLACE AFTER THE TEXT ABOVE]

Jessica Rose prepared the chart above illustrating female preponderance in having disability from adverse events following C19 “vaccine” treatments across all age groups.

Ed Dowd’s group found similar pattern of women diverging sharply upward from men in disability event reporting in VAERS as the GTP program ramped up. (https://phinancetechnologies.com/HumanityProjects /US%20Disabilities%20-%20Part1.htm) Below is a plot of Dr. Rose’s data showing men narrowing the gap in the 12-to 17-age bracket with respect to disability followed by female dominance of the statistic until the gap begins to narrow after age 50.

[IMAGE 9 — ORIGINAL SOURCE PAGE 238; PLACE AFTER THE TEXT ABOVE]

Females account for 64% of the disabled from adverse events in the entire data set of 30,532 disability event reports.

III. CoVax Disease and Youth: Conception Through Early Adulthood This section will look at a number of significant medical problems following GTPs affecting youth beginning in utero.

A. In Utero, Miscarriage/Stillbirth The recent release of Pfizer document, Appendix 2.2, reporting on the cumulative data collection through June 2022 and the interval of December 19, 2021, through June 18, 2022. (https://www.globalresearch.ca /wp-content/uploads/2023/05/pfizer-report.pdf) There were a total of 1,485,027 cases with 4,964,106 total adverse events. Dr. Rose has pulled out the following data from this document. (https://open.substack.com/pub/jessicar/p /pfizer-appendix-22-document-compared)

Female menstrual dysfunction was reported in 129,988 adverse events as of a year ago (06/18/2022 with 16% considered serious (below)). There were 35,534 reports of excessive bleeding/hemorrhage with 22% of the events considered serious.

[IMAGE 10 — ORIGINAL SOURCE PAGE 239; PLACE AFTER THE TEXT ABOVE]

Interfering with normal ovarian/menstrual functions has consequences. Below is the data from OpenVAERS showing a spike in miscarriages and stillbirths as the LNP/mRNA dosing program ramped up. The following table from OpenVAERS lists almost 5,000 miscarriages or stillbirths; 36,765 menstrual disorders; vaginal/uterine hemorrhage in 12,871; and over 1,000 fetal defects as of May 12, 2023.

Applying the URF of 41 from Kirsch et al. gives the following estimates of the true numbers.

These are sobering numbers. By comparison, it has been estimated that thalidomide caused 10,000 cases of birth defects in Europe from 1957 to 1961 before it was pulled from the market. Like spike-producing drugs, thalidomide was never tested in pregnant women and yet was aggressively marketed to them for morning sickness. (https://www .drugs.com/monograph/thalidomide.html)

[IMAGE 11 — ORIGINAL SOURCE PAGE 240; PLACE AFTER THE TEXT ABOVE]

Francis Kelsey of the FDA is credited with preventing use of thalidomide in the United States and, in doing so, ushered in the modern era at the FDA beginning in 1960 and ending in 2020, when the FDA/CDC shifted from protector to perpetrator. (https://www.fda.gov/about-fda/fda-history-exhibits /frances-oldham-kelsey-medical-reviewer-famous-averting-public-health-tragedy) The miscarriage/stillbirth event reporting in VAERS shows a crescendo pattern as GTP population dosing ramped up in 2021 followed by a drop-off in 2022.

What is the physiological connection between perinatal adverse events for mother and child and the C19 gene therapy drugs? Dr. Arne Burkhardt, MD, a recently deceased pathologist in Reutlingen, Germany, organized a 10-member team of pathologists, coroners, and scientists to study the histopathology of C19 vaccine organ and tissue damage in autopsy and biopsy specimens from about 130 subjects. The Burkhardt Group’s seminal work establishing the pathological basis of CoVax Disease has been presented in Parts 1 and 2 of this series. (https://dailyclout.io/report-56-autopsies-reveal-the-medical-atrocities -of-genetic-therapies-being-used-against-a-respiratory-virus/, https://dailyclout.io/report-58-part-2-autopsies -reveal-medical-atrocities-of-genetic-therapies-being-used-against-a-respiratory-virus/)

[IMAGE 12 — ORIGINAL SOURCE PAGE 241; PLACE AFTER THE TEXT ABOVE]

Dr. Burkhardt’s group identified the histopathology of harms associated with C19 gene therapy products in ovaries positive staining for spike protein Top Left, lymphocytic infiltration in the uterus (endometrium) Top Right, spike protein in placenta Bottom Left, and spermatozoa depletion in testes Bottom Right (previous image). The mechanisms of these harms were diverse and varied from vasculitis, protein deposition, inflammation, necrosis, and neoplasia. Not surprisingly, GTPs have been linked to a decline in live births around the globe.

“Nine Months Post-COVID mRNA ‘Vaccine’ Rollout, Substantial Birth Rate Drops in 13 European Countries, England/Wales, Australia, and Taiwan.” (https://dailyclout.io/report-52-nine-months-post -covid-mrna-vaccine-rollout-substantial-birth-rate-drops/)

B. Neonatal/Breast Milk Pfizer Confidential Document 5.3.6 reporting on the first 10 weeks of widespread use of BNT162b2—up to February 28, 2021, in the U.S. and 12 weeks in the United Kingdom—identified a problem with nursing mothers who received BNT162b2 while breastfeeding:

Keep in mind that follow-up for the “No Adverse Events” is not provided by the CDC, thus calling into question the accuracy of these numbers. There were four serious fetus baby cases and one neonatal death. Thirteen percent of the 133 breastfeeding infants had 19 different reactions. (https://dailyclout.io/pfizer-evidence-so-far-coverups-heart-damage-and -more/) Meanwhile, breastfeeding mothers experienced the following:

Given these reactions were observed early in the release of BNT162b2, it was not too surprising to see the study by Hanna et al. who reported detecting mRNA from C19 “vaccines” in breast milk (following image).

[IMAGE 13 — ORIGINAL SOURCE PAGE 242; PLACE AFTER THE TEXT ABOVE]

(https://jamanetwork.com/journals/jamapediatrics/fullarticle/2796427)

Of 11 lactating individuals enrolled, trace amounts of BNT162b2 and mRNA-1273 COVID-19 mRNA vaccines were detected in 7 samples from 5 different participants at various times up to 45 hours postvaccination (Table 2).

The sporadic presence and trace quantities of COVID-19 vaccine mRNA detected in EBM suggest that breastfeeding after COVID-19 mRNA vaccination is safe, particularly beyond 48 hours after vaccination [italics and bold added]. These data demonstrate for the first time to our knowledge the biodistribution of COVID-19 vaccine mRNA to mammary cells and the potential ability of tissue EVs to package the vaccine mRNA that can be transported to distant cells.

Remarkably, the authors concluded that mRNA in breast milk was safe.

[IMAGE 14 — ORIGINAL SOURCE PAGE 243; PLACE AFTER THE TEXT ABOVE]

In May of this year a report was issued by Sonia Elijah in Children’s Health Defense Europe (above) identifying in infants two cases of stroke after being exposed to mRNA-containing breast milk, three cases of severe neurologic disease, and four cases of respiratory Adverse Events of Special Interest (AESIs). (https://soniaelijah.substack.com/p/emas-latest-bombshell-instalment) Meanwhile, a Freedom of Information Act (FOIA) request for records from the CDC turned up the following email in which John Su reported seeing “. . . a fair bit of ‘exposure by breast milk’- does that indicate an increase in reporting of this particular PT?” (https://jackanapes.substack.com/p/wake-up-and-smell-the-glitch-in-the)

The email goes on to note errors in administering the C19 drug products to children aged five-to 11-yearsold. This subject will be addressed more fully in Section IIIC, on administrative errors, to follow. John Su goes on to note “vaccine failure” was on the increase, as was known from Pfizer Confidential Document 5.3.6, February 28, 2021. VAERS contains documentation of 38 cases of symptoms reported after breastfeeding infants’ exposure to mRNA from their mother’s milk:

[IMAGE 15 — ORIGINAL SOURCE PAGE 244; PLACE AFTER THE TEXT ABOVE]

VAERS ID 1415059 (below) documents a three-month-old female who received mRNA1273 in her mother’s breast milk and had a seizure lasting seven minutes the same day as her mother’s inoculation. She was hospitalized for two days. The report was completed three days after the seizure with no outcome information other than the child was considered to have permanent disability. The CDC does collect outcome information but does not share it.

VAERS ID 1166062 (below) was a four-month-old male who died three days after his mother’s second dose of BNT162b2. The cause of death was failure to thrive, fever, and a hematologic condition known as thrombotic thrombocytopenic purpura.

[IMAGE 16 — ORIGINAL SOURCE PAGE 245; PLACE AFTER THE TEXT ABOVE]

These are a sample of similar cases in VAERS. Dr. Makis has published a recent article on LNP/mRNA-related neonatal fatalities. (https://open.substack.com/pub/makismd/p/mrna-and-pregnancy-infants-who-died)

C. Administrative Issues Have Consequences: Ages Zero to 17 Years

VAERS through 5/12/2023 C19 Gene Therapy Drugs U.S. and Territories

Administrative errors occurred in 24% (37,235/153,198) of all reported events in children ages zero-to 17-yearsold. (VAERS) The most common by far is administration of the product to children and adolescents too young to receive the drug. Was this a byproduct of the $1 billion campaign to scare and cajole parents into having their children injected to keep them safe? Follow-up on these administrative errors, like the one below, has not been posted if it exists.

Some of these errors have had disastrous complications. This search result gives more detail on the “No Adverse Effects,” Death, Life Threatening, and Permanent Disability (following image).

[IMAGE 17 — ORIGINAL SOURCE PAGE 246; PLACE AFTER THE TEXT ABOVE]

VAERS ID 2457513: This 15-year-old girl had an injection that was coded “Product Administered to Patient of Inappropriate Age.” After her second dose of mRNA-1273 (Moderna), she had a cardiac arrest and died. Why was a 15-year-old receiving an injection to “prevent” C19 classified as a “PATIENT”?

“The benefit risk relationship of m/RNA-1273 is not affected by this report.” Why would anyone say something like that after a 15-year-old, otherwise healthy girl died after receiving a failed “vaccine”? VAERS ID 1772015, “Inappropriate Schedule of Product Administration,” also concerns a 15-year-old— this time a boy. Four days following dose two of Pfizer’s BNT162b2, the teen developed multifocal hemorrhagic lesions in his brain: cerebrum, brainstem, and cerebellum (following chart).

[IMAGE 18 — ORIGINAL SOURCE PAGE 247; PLACE AFTER THE TEXT ABOVE]

He was considered permanently disabled at age 15 years. The topic of administrative errors and their consequences is worthy of a separate report given that there were over 37,000 of them. Applying the URF of 41, that works out to 1,526,635 medication errors of various types.

D. Cardiac Arrest

VAERS through 5/12/2023

[IMAGE 19 — ORIGINAL SOURCE PAGE 248; PLACE AFTER THE TEXT ABOVE]

Across all ages and since 1990, the mRNA products account for more than half of all vaccine-related cardiac arrests in VAERS (previous image).

Males had 59% of the cardiac arrest events reported to VAERS in 2021, the first year of the GTPs. The fatality rate was 72% for females and 76% for males. The age bracket from 65 to 79 years of age had the greatest number of reports. There were 62 event reports for < 30 years-of-age. With an URF of 41 that results in 2,501 cardiac arrests in this age bracket. The following cases from VAERS are typical cardiac arrest cases, except these are children (ages six to 17), not septuagenarians.

[IMAGE 20 — ORIGINAL SOURCE PAGE 249; PLACE AFTER THE TEXT ABOVE]

E. Central Nervous System and Neurological Disease: Co-VAN Cluster Samim et al. performed an extensive literature review of neurologic diseases associated with the C19 gene therapy drugs and organized them under the heading of Co-VAN (COVID-19 vaccine-associated neurological diseases) as illustrated below.

The Co-VAN Disease group fits well in a taxonomy of CoVax Disease based on organ systems and pathological processes associated with spike-generating drugs. This topic will be further developed in Part 5 of this series. There is wide variation in the manifestations of neurological disease following spike-generating drugs from peripheral neuropathy to demyelinating disorders to stroke, seizures, encephalitis, protein deposition disease, and cranial neuropathies, such as Bell’s Palsy or Ramsay Hunt Syndrome (cranial nerve VII). Pfizer Confidential Document 5.3.6 summarized adverse events and Adverse Events of Special Interest (AESIs) from December 2020 through February 2021. The following histogram summarizes the neurological diseases identified from a pool of over 40,000 GTP subjects reporting complications after receiving BNT162b2.

[IMAGE 21 — ORIGINAL SOURCE PAGE 250; PLACE AFTER THE TEXT ABOVE]

In spite of this significant “signal,” C19 gene therapy products were mandated by governments throughout the world. Not surprisingly, neurologic complications appeared in children as OpenVAERS summarizes below.

(https://openvaers.com/covid-data/child-summaries)

[IMAGE 22 — ORIGINAL SOURCE PAGE 251; PLACE AFTER THE TEXT ABOVE]

Overall, there were 5,220 neurological events ranging from 4,549 with migraine to 49 with cerebral hemorrhage/aneurysm in ages six months to 17 years. The estimates with an URF of 41 are given below. These are significant medical problems that often leave permanent impairment and disability.

i. Acute Disseminated Encephalomyelitis (ADEM) ADEM is a rare autoimmune demyelinating central nervous system disease, typically associated with patients younger than 15 years of age. Encephalitis is an inflammatory condition of the brain tissue known as myelin (the tissue coating nerve fibers and maintaining normal function of the nerves). Dr. Burkhardt’s collection contains histopathological evidence of inflammation of both brain and the membranes around it.

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043599/)

Brock et al. present the following case of a 10-year-old, previously healthy female who presented with progressive lower extremity weakness, paresthesia, and urinary retention.

Case Report A 10-year-old female with no past medical history presented to Golisano Children’s Hospital, Fort Myers, Florida, United States on December 21, 2021 [sic] with 7 days of progressive lower extremity weakness, paresthesia, and urinary retention. No recent symptoms of infection were reported.

[IMAGE 23 — ORIGINAL SOURCE PAGE 252; PLACE AFTER THE TEXT ABOVE]

Neurological examination showed mild lower extremity hyperreflexia, right lower extremity weakness with inability to ambulate, a mild pronator drift, and a right visual field defect. The patient received her second dose of mRNA-based COVID-19 vaccine 16 days prior to the onset of symptoms. Upon admission, a comprehensive laboratory assay including CBC, CMP, ESR, and CRP, was negative. A respiratory viral panel which included SARS-COV2 PCR testing was negative. Contrastenhanced MRI of the brain demonstrated multiple prominent T2/FLAIR hyperintense subcortical and deep white matter lesions with incomplete rim-enhancement, compatible with active demyelination, and avid peripheral diffusion restriction (Figure 1) Emphasis added.

[IMAGE 24 — ORIGINAL SOURCE PAGE 253; PLACE AFTER THE TEXT ABOVE]

Contrast-enhanced MRI of the cervical, thoracic, and lumbar spine demonstrated a long-segment, non-expansile, partially enhancing intramedullary lesion within the thoracic spinal cord, also most likely compatible with active demyelinating process (Figure 2 above). There were no findings suggestive of Guillain-Barré syndrome. Secondary differential considerations included transverse myelitis, CNS lymphoma, and atypical multiple sclerosis. Three months after initial evaluation, the patient returned for outpatient neurologic follow-up. She reported mild fatigue. Examination showed a mild, persistent gait instability and hip muscle weakness. All other symptoms were resolved. A few days later, final histopathology showed white matter neurons with an extensive macrophage-rich inflammatory infiltrate with small lymphocytic component forming perivascular aggregates (Figure 3).

Luxol/H&E stain showed severe loss of myelin, with macrophages demonstrating phagocytosed myelin debris. Immunohistochemistry showed depletion, but relative preservation of axons, with scattered perivascular accumulations of CD3+ T-cells and CD4/CD8 co-expressing T-cells. (Bold added.)

[IMAGE 25 — ORIGINAL SOURCE PAGE 254; PLACE AFTER THE TEXT ABOVE]

Widespread neurologic damage is well-documented in this case. Residual impairment and disability are probable. VAERS ID 1948381 concerns an 11-year-old male with onset of ADEM three weeks after injection of flu vaccine along with BNT162b2 on November 17, 2021. MRI evaluation revealed abnormalities throughout the cerebral cortex with extension into adjacent tissues. The child was admitted to the hospital for five days during which he received high-dose steroids.

The report was filled out on December 14, 2021, while the child was still in the acute phase of his illness, which began on December 6, 2021, only three days following hospital discharge; so, no outcome determination was possible even though the report indicated no death or disability. Residual impairment examination after one year is required.

ii. Aneurysm/Cerebral Hemorrhage

[IMAGE 26 — ORIGINAL SOURCE PAGE 255; PLACE AFTER THE TEXT ABOVE]

The pathomechanism of spike-producing drug-associated aneurysm was well described by Dr. Burkhardt’s Group in Parts 1 and 2 of this series. Briefly, vascular endothelium (inner lining) is attacked by either spike and related proteins or by activated leukocytes that disrupt the inner lining of an artery which leads to a rupture of the vessel wall, dissection of blood by arterial pressure through the muscular layer with dilatation of the vessel wall or rupture, or both.

VAERS ID 1963633: This 15-year-old girl received her second dose of BNT162b2 on June 19, 2021, and passed away on December 17, 2021, after a very complicated 17 days in the hospital.

The consequences of an aneurysm can be dire not only for the injured but the loved ones who suffer while they helplessly watch as their child dies.

[IMAGE 27 — ORIGINAL SOURCE PAGE 256; PLACE AFTER THE TEXT ABOVE]

iii. Stroke The father’s words in the image below tell the story pretty well.

Childhood stroke has been reported to occur in 1 to 13 per 100,000 children. (Pediatric Stroke: A Review, Tsze and Valente, Emerg Med Int. 2011; 2011: 734506. Published online 2011 Dec 27. doi: 10.1155/2011/734506 PMCID: PMC3255104 PMID: 22254140, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255104/.) Unfortunately, denominators to properly calculate prevalence rates are lacking with GTPs. Pfizer Confidential Document 5.3.6 reports a seven-year-old child who received BNT162b2 long before pediatric dosing was developed and long before the emergency use authorization (EUA) was extended to children. This is another example of the sloppy administration of the “vaccine” program. Dr. Makis and Professor Miller, independently of one another, maintain archives of CoVax Disease cases culled from the media (links below). (https://makismd.substack.com) and (https://markcrispinmiller.substack.com) Edward Dowd’s book, Dowd, Ed. “Cause Unknown”: The Epidemic of Sudden Deaths in 2021 & 2022. Skyhorse Publishing, 2023 is a similar archive of sudden deaths along with statistical data.

F. Autoimmunity and Immunologic Effects Autoimmunity was featured in Part 4C of this series. (https://dailyclout.io/report-70-part-4c-clinical-evidence -supporting-the-hypothesis-that-autoimmunity-is-one-of-the-principal-pathological-mechanisms-of-harm-fromcovid-19-gene-therapy-drugs/) Briefly, autoimmunity is a process in which one’s immune system attacks “self” thus producing an illness through the process of inflammation, often with system-wide effects although more localized varieties exist such as thyroiditis and diabetes type I.

[IMAGE 28 — ORIGINAL SOURCE PAGE 257; PLACE AFTER THE TEXT ABOVE]

Eighty-five percent of autoimmune diseases following vaccination in the past 10 years have followed the public introduction of C19 gene therapy drugs. Females dominate the 18-to 29-year-old bracket.

VAERS ID 1486812: This 12-year-old girl (above) developed autoimmune thyroiditis 49 days after dose two of BNT162b2. CoVax illnesses often resemble known illnesses, but, as in this case with “massive” hair loss, something is unique in many of them.

[IMAGE 29 — ORIGINAL SOURCE PAGE 258; PLACE AFTER THE TEXT ABOVE]

G. Multisystem Inflammatory Syndrome in Children (MIS-C)

MIS-C is an inflammatory process that involves multiple organs and physiological systems simultaneously or in sequence, sometimes mild at first but proceeding rapidly at times to critical illness. MIS-C was discussed in Part 4C of this series. (https://dailyclout.io/report-70-part-4c-clinical-evidence-supporting-the-hypothesis -that-autoimmunity-is-one-of-the-principal-pathological-mechanisms-of-harm-from-covid-19-gene-therapy -drugs/)

VAERS through 5/12/2023

[IMAGE 30 — ORIGINAL SOURCE PAGE 259; PLACE AFTER THE TEXT ABOVE]

Males are afflicted in 59% of reported cases (left histogram of previous image). There were no cases reports from 2020, but 106 were reported in 2021 and then, in 2022, the reports dropped to 27 as the spike drug use declined (right histogram). As noted, prior to rollout of the C19 “vaccines,” there were no MIS-C cases in VAERS. As the public’s willingness to participate in the inoculation with C19 “vaccines” waned, so did the reports of MIS-C as shown in the right histogram above.

VAERS ID 2327226: This eight-year-old girl was not so fortunate as others and passed away four months following her second dose of BNT162b2. She was febrile for three weeks before being admitted to the hospital for multiple organ system failure. Her organ involvement included lymph nodes, skin, heart, intestines, lungs, and liver.

The final two sentences need emphasis: “By the second treatment, her belly started getting distended, her lungs filled with liquids. She was transferred to ICU and her heart stopped beating right there.”

[IMAGE 31 — ORIGINAL SOURCE PAGE 260; PLACE AFTER THE TEXT ABOVE]

Six cases from VAERS are summarized below. All six of these youngsters survived. There has been no assessment and reporting of impairment and disability in survivors.

This category of CoVax Disease, MIS-C, is another example of complex and aggressive illness following GTPs.

H. Myocarditis/Pericarditis

The pericardium is a fibrous tissue layer surrounding the heart. Inflammation of this sac-like structure can compromise cardiac function.

[IMAGE 32 — ORIGINAL SOURCE PAGE 261; PLACE AFTER THE TEXT ABOVE]